Do analysts rate ICCC or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, ICCC or ALVR?

ImmuCell has higher revenue and earnings than AlloVir. ImmuCell is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuCell $27.64M 3.37 -$1.04M -$0.06 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is ICCC or ALVR more profitable?

AlloVir has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell -1.82% -1.88% -1.22% AlloVir N/A -71.03% -61.27%

Do analysts recommend ALVR or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, ALVR or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is ALVR or TELO more profitable?

AlloVir's return on equity of -71.03% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Telomir Pharmaceuticals N/A -201.23% -172.71%

Do analysts prefer IBIO or ALVR?

iBio currently has a consensus target price of $5.00, indicating a potential upside of 197.62%. Given iBio's stronger consensus rating and higher probable upside, research analysts clearly believe iBio is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, IBIO or ALVR?

iBio has higher revenue and earnings than AlloVir. iBio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $300K 278.20 -$18.38M -$0.58 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is IBIO or ALVR more profitable?

iBio's return on equity of -53.86% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% AlloVir N/A -71.03% -61.27%

Do analysts prefer ALVR or BTMD?

biote has a consensus target price of $2.75, indicating a potential upside of 26.73%. Given biote's stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, ALVR or BTMD?

biote has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A biote $192.22M 0.42 $27.05M $0.44 4.93

Is ALVR or BTMD more profitable?

biote has a net margin of 8.29% compared to AlloVir's net margin of 0.00%. biote's return on equity of -25.72% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% biote 8.29% -25.72% 15.12%

Do analysts rate RLYB or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, RLYB or ALVR?

Rallybio has higher revenue and earnings than AlloVir. Rallybio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rallybio $860K 97.43 -$8.98M -$4.34 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is RLYB or ALVR more profitable?

AlloVir has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets Rallybio -911.07% -55.79% -51.48% AlloVir N/A -71.03% -61.27%

AlloVir (ALVR) Competitors

$4.75 +0.22 (+4.86%)

As of 07/2/2026

Compare

ALVR vs. ICCC, TELO, IBIO, BTMD, and RLYB

Should you buy AlloVir stock or one of its competitors? MarketBeat compares AlloVir with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AlloVir include ImmuCell (ICCC), Telomir Pharmaceuticals (TELO), iBio (IBIO), biote (BTMD), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry.

How does AlloVir compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

In the previous week, ImmuCell's average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.

Company	Overall Sentiment
ImmuCell	Neutral
AlloVir	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AlloVir has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
AlloVir	N/A	-71.03%	-61.27%

ImmuCell has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ImmuCell has higher revenue and earnings than AlloVir. ImmuCell is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.37	-$1.04M	-$0.06	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Summary

ImmuCell beats AlloVir on 6 of the 11 factors compared between the two stocks.

How does AlloVir compare to Telomir Pharmaceuticals?

AlloVir (NASDAQ:ALVR) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

In the previous week, AlloVir's average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
Telomir Pharmaceuticals	Neutral

AlloVir's return on equity of -71.03% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Summary

AlloVir beats Telomir Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does AlloVir compare to iBio?

iBio (NASDAQ:IBIO) and AlloVir (NASDAQ:ALVR) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

iBio has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

iBio has higher revenue and earnings than AlloVir. iBio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$300K	278.20	-$18.38M	-$0.58	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

iBio's return on equity of -53.86% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
AlloVir	N/A	-71.03%	-61.27%

7.9% of iBio shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

iBio currently has a consensus target price of $5.00, indicating a potential upside of 197.62%. Given iBio's stronger consensus rating and higher probable upside, research analysts clearly believe iBio is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, iBio had 4 more articles in the media than AlloVir. MarketBeat recorded 4 mentions for iBio and 0 mentions for AlloVir. iBio's average media sentiment score of 0.16 beat AlloVir's score of 0.00 indicating that iBio is being referred to more favorably in the media.

Company	Overall Sentiment
iBio	Neutral
AlloVir	Neutral

Summary

iBio beats AlloVir on 12 of the 15 factors compared between the two stocks.

How does AlloVir compare to biote?

AlloVir (NASDAQ:ALVR) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, biote has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

66.1% of AlloVir shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, AlloVir's average media sentiment score of 0.00 equaled biote'saverage media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
biote	Neutral

biote has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
biote	$192.22M	0.42	$27.05M	$0.44	4.93

biote has a consensus target price of $2.75, indicating a potential upside of 26.73%. Given biote's stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

biote has a net margin of 8.29% compared to AlloVir's net margin of 0.00%. biote's return on equity of -25.72% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
biote	8.29%	-25.72%	15.12%

Summary

biote beats AlloVir on 13 of the 14 factors compared between the two stocks.

How does AlloVir compare to Rallybio?

Rallybio (NASDAQ:RLYB) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Rallybio's average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.

Company	Overall Sentiment
Rallybio	Neutral
AlloVir	Neutral

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Rallybio has higher revenue and earnings than AlloVir. Rallybio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	97.43	-$8.98M	-$4.34	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Rallybio has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AlloVir has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-55.79%	-51.48%
AlloVir	N/A	-71.03%	-61.27%

Summary

Rallybio beats AlloVir on 7 of the 11 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVR vs. The Competition

Export

Metric	AlloVir	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.95M	$353.15M	$7.16B	$12.48B
Dividend Yield	N/A	N/A	2.66%	6.52%
P/E Ratio	-0.23	N/A	28.02	24.70
Price / Sales	N/A	228.84	540.37	99.49
Price / Cash	N/A	22.44	49.26	57.09
Price / Book	0.16	4.86	10.96	6.46
Net Income	-$190.42M	-$141.03M	$3.57B	$337.01M
7 Day Performance	9.95%	2.78%	2.12%	1.69%
1 Month Performance	1.93%	7.12%	5.25%	3.81%
1 Year Performance	90.00%	77.98%	33.29%	23.90%

AlloVir Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVR AlloVir	N/A	$4.75 +4.9%	N/A	+90.0%	$23.95M	N/A	N/A	110	High Trading Volume
ICCC ImmuCell	0.7057 of 5 stars	$9.86 +1.2%	N/A	+53.2%	$88.16M	$27.64M	N/A	70	Positive News
TELO Telomir Pharmaceuticals	0.1491 of 5 stars	$1.25 -2.3%	N/A	+7.6%	$88.03M	N/A	N/A	1	Positive News
IBIO iBio	3.3721 of 5 stars	$1.65 -5.2%	$5.00 +203.0%	N/A	$86.44M	$400K	N/A	100	News Coverage Positive News Analyst Forecast
BTMD biote	4.3043 of 5 stars	$2.15 -4.4%	$2.75 +27.9%	-48.5%	$84.56M	$192.22M	4.89	194	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AlloVir (ALVR) Competitors